Trials / Completed
CompletedNCT00409929
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071
A Randomized, Double-blind, Placebo-controlled, Time Lagged, Parallel Group, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AEB071 Doses Greater Than 500 mg in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and tolerability of ascending single oral doses greater than 500 mg of AEB071 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AEB071 |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2006-07-01
- First posted
- 2006-12-12
- Last updated
- 2010-10-19
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00409929. Inclusion in this directory is not an endorsement.